Eyetronic Therapie

Eyetronic Therapie, formerly known as EBS Technologies, is a medical technology company established in 2007 and based in Germany. The company is focused on developing treatments for patients with vision loss resulting from neuropathies of the optic nerve, such as glaucoma. This condition affects millions worldwide and is a leading cause of irreversible blindness.

Eyetronic has developed a non-invasive therapeutic device that uses alternating current stimulation to treat optic nerve damage. The core of its business is the Eyetronic® Therapy, which applies gentle, individually adjusted electrical pulses to the optic nerve. This process aims to stimulate the metabolism of retinal ganglion cells that are damaged but not destroyed, with the dual goals of preventing further cell degeneration and reactivating nerve tissue to restore vision. The therapy is grounded in clinical research suggesting that electrical stimulation can facilitate the survival and regeneration of these crucial nerve cells.

The treatment protocol consists of ten sessions, each lasting between 60 to 90 minutes, administered over ten consecutive business days. It is delivered via a system that includes stimulation goggles with embedded electrodes. The technology has secured a CE mark, signifying compliance with European health and safety standards for medical devices, and is protected by patents in the EU, Japan, and the USA. Treatment is available in selected centers across several European countries, including Germany, Switzerland, Italy, and Spain.

Since its founding, the company has progressed through multiple funding stages, securing a total of $5.4 million over four rounds from investors such as HTGF, Earlybird, and Brandenburg Capital. Its first funding round was a seed round in March 2009, followed by subsequent rounds including a Series B in 2013 and a Series A in 2015. The company is now expanding its reach, with a clinical trial underway in the United States to evaluate the therapy's effectiveness for glaucoma patients, with preliminary results anticipated in early 2026.

Keywords: Eyetronic Therapie, optic nerve stimulation, glaucoma treatment, vision restoration, non-invasive therapy, EBS Technologies, medical device, neuropathies, neuroprotection, neurorestoration, retinal ganglion cells, CE mark, visual field loss, electrical stimulation, alternating current stimulation, HealthTech, vision therapy, optic nerve damage, clinical trial, ophthalmic diseases